In June 2020 we announced the success of the EuCanImage Consortium, whose €10-million grant proposal was selected for funding by the European Commission and launched a few months later in October 2020.
EuCanImage will build a federated, secure and scalable European cancer imaging platform, with capabilities that will enhance the potential of artificial intelligence in oncology.
One year on and the project is starting to produce published results. Research findings are available free of charge and there is open access to published papers and reports here: eucanimage.eu/research-results. The list will be updated as the project progresses.
Current papers at time of writing:
-
- November 2020: “Non-invasive imaging prediction of tumor hypoxia: A novel developed and externally validated CT and FDG-PET-based radiomic signatures”
S. Sanduleanu et al., Radiotherapy and Oncology - February 2021: “Prognostic and Predictive Value of Integrated Qualitative
and Quantitative Magnetic Resonance Imaging Analysis in Glioblastoma”
M. Verduin et al., Cancers - March 2021: “Data preparation for artificial intelligence in medical imaging: A comprehensive guide to open-access platforms and tools”
O. Diaz et al., Physica Medica - April 2021: “Development and external validation of a non-invasive molecular status predictor of chromosome 1p/19q co-deletion based on MRI radiomics analysis of Low Grade Glioma patients”
R. Casale et al., European Journal of Radiology
- November 2020: “Non-invasive imaging prediction of tumor hypoxia: A novel developed and externally validated CT and FDG-PET-based radiomic signatures”
The project will run for four years, ending in 2024. The European Association for Cancer Research are proud to be a partner in the EuCanImage Consortium.
